financetom
Business
financetom
/
Business
/
Merck stops skin cancer combination therapy testing in late-stage study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Merck stops skin cancer combination therapy testing in late-stage study
May 13, 2024 4:39 AM

May 13 (Reuters) - Merck ( MRK ) said on Monday it had

discontinued the arm of a late-stage study, which tested an

experimental antibody-based drug with its blockbuster

immunotherapy Keytruda for some patients with the most severe

form of skin cancer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved